{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:12:54Z","timestamp":1789384374830,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2778,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.bbmt.2007.06.005","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T07:53:21Z","timestamp":1187078001000},"page":"1095-1105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"13","author":[{"given":"Seong-Gil","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Jun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miee","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Hye","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun Seop","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Jeong","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Song","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Cheol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Beom","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoo-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2007.06.005_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2007.06.005_bib2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib3","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V80.7.1648.1648","article-title":"Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation","volume":"80","author":"Copelan","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib4","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d\u2019Etudes de la Greffe de Moelle Osseuse","volume":"79","author":"Blaise","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood.V81.8.2187.2187","article-title":"A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study","volume":"81","author":"Blume","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib6","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib7","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","article-title":"A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group","volume":"83","author":"Ringden","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib8","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM)","volume":"85","author":"Devergie","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulfan bioavailability","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib10","first-page":"759","article-title":"Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?","volume":"14","author":"Schuler","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2007.06.005_bib12","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib13","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib14","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib15","first-page":"6402","article-title":"Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors","volume":"47","author":"Peters","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2007.06.005_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002800050404","article-title":"Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy","volume":"37","author":"Bhagwatwar","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2007.06.005_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.bmt.1702823","article-title":"Pharmacokinetics of liposomal busulphan in man","volume":"27","author":"Hassan","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib18","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401921","article-title":"A phase I\/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation","volume":"14","author":"Olavarria","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2007.06.005_bib19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","article-title":"Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation","volume":"8","author":"Fernandez","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2007.06.005_bib22","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/sj.bmt.1702351","article-title":"Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)","volume":"25","author":"Andersson","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1083-8791(99)70007-8","article-title":"Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model","volume":"5","author":"Deeg","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib24","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","article-title":"Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia","volume":"84","author":"Shaw","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.bmt.1702504","article-title":"Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study","volume":"26","author":"Choi","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.V61.2.318.318","article-title":"Cyclosporin-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants","volume":"61","author":"Tutschka","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bmt.1701983","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation","volume":"24","author":"Przepiorka","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2007.06.005_bib31","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/jcm.21.2.217-221.1985","article-title":"Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens","volume":"21","author":"Gleaves","year":"1985","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bbmt.2007.06.005_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/14737159.4.2.231","article-title":"Rapid detection of cytomegalovirus infection in transplant patients","volume":"4","author":"Pancholi","year":"2004","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.bbmt.2007.06.005_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1096-9071(199909)59:1<91::AID-JMV15>3.0.CO;2-K","article-title":"Comparison of cytomegalovirus antigenemia and culture assays in patients on and off antiviral therapy","volume":"59","author":"St George","year":"1999","journal-title":"J Med Virol"},{"key":"10.1016\/j.bbmt.2007.06.005_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/bbmt.2002.v8.abbmt080619","article-title":"A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan","volume":"8","author":"Vaughan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a completing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2007.06.005_bib37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib38","first-page":"285","article-title":"Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan","volume":"90","author":"Kim","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2007.06.005_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2007.06.005_bib40","first-page":"6203","article-title":"Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study","volume":"50","author":"Vassal","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2007.06.005_bib41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":"Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib42","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","article-title":"High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients","volume":"20","author":"Ljungman","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2007.06.005_bib44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2004.07.010","article-title":"Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"10","author":"Tran","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2007.06.005_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cca.2005.12.011","article-title":"Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan","volume":"368","author":"Kusama","year":"2006","journal-title":"Clin Chim Acta"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879107003199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879107003199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:29:57Z","timestamp":1761056997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879107003199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1083879107003199"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2007.06.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2007.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}